Moderna (MRNA +5.87%) may finally have the catalyst investors have been waiting for beyond COVID. A successful Phase 3 melanoma study strengthens the case for personalized mRNA cancer treatment, but the stock's huge rerating now leaves one question dominant: Can this become a durable oncology franchise, or has the market moved faster than the evidence?
Read on fool.com